Monograph

C09CA06 - Candesartan

Not porphyrinogenic

Rationale

Mainly eliminated in unchanged form, in minor parts metabolised by CYP 2C9. One reference and clinical observations point to non- porphyrinogenicity.

Chemical description

Angiotensin II receptor antagonist. Mainly eliminated in unchanged form, to a lesser extent metabolized in the liver by 2C9. Less potent inhibitor of CYP 2C9. Thunell, patient reports (n=5): tolerated. Andersson, patient report (n=1): tolerated. French list: authorized

IPNet drug reports

Uneventful use reported in 44 patients with acute porphyria.

Similar drugs

Explore alternative drugs in similar therapeutic classes C09C / C09CA or go back.

Tradenames

This list comprises raw data collected from different countries. In some cases, a more comprehensive list of available drug packages is included. Consequently, very similar terms may therefore appear multiple times. Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Show more details and information about the listed tradenames